Universal vaccine for colds, flu, and Covid developed – and it could actually be effective

 

Traditionally, vaccines function by training the immune system to identify a particular virus or bacterium, effectively showing it a wanted poster for a single culprit.

But what if a single vaccine could guard against multiple infections simultaneously?

A group of researchers has created a possible candidate for such a vaccine, with encouraging results from a recent study on mice, published in the journal Science.

Typically, vaccines expose the immune system to a specific pathogen—either a weakened variant or a critical protein from its surface—allowing the body to recognize and combat it if encountered later.

This particular vaccine takes an entirely different route.

Instead of focusing on a single pathogen, it includes molecules that imitate the signals the body produces during an attack from a virus or bacterium.

As a result, certain immune cells are placed in a heightened state of alert, prepared to respond quickly to various threats instead of just one.

However, the implications of stimulating the immune system beyond its usual state will only be understood after human trials are carried out.

Why use a nasal spray instead of an injection?

The nose, throat, and lungs are covered by what scientists refer to as mucosal surfaces—moist tissues that serve as the body’s primary interface with the environment and its first line of defense against infections.

The immune response in these areas is more robust when a vaccine is administered directly there, as opposed to being injected into an arm muscle.

This concept is already implemented in the routine flu vaccine provided to young children in Britain, which is administered as a nasal spray.

Studies have also indicated that Covid vaccines can more effectively block infection in animals when given this way rather than through injection.

By administering the new vaccine through the nose, it reaches immune cells deep within the lungs.

How does it function?

The vaccine enhances the interaction between two essential categories of immune cells.

The first type consists of alveolar macrophages, large cells located in the small air pockets of the lungs, where they serve as an initial defense against any harmful substances that are inhaled.

When activated by the vaccine, they can swallow and eliminate invading pathogens much more quickly than they normally do.

The second type is T cells, which are stimulated to generate swifter antiviral reactions.

Since the vaccine strengthens these general frontline defenses instead of targeting particular pathogens, it theoretically has the potential to combat a wide array of threats.

In studies with mice, it also seemed to reduce allergic responses – such as those to house dust mites – because the robust inflammatory immune response it initiates seems to counteract the different response that causes allergies.

Will it function the same in humans?

There are significant differences between the immune systems of mice and humans, and successful results in animal studies often do not apply to human subjects.

The essential next phase will involve controlled studies of human infections – trials where healthy participants receive the vaccine, are exposed to a specific pathogen under close medical monitoring, and are assessed meticulously for both safety and immune reactions.

If proven effective in humans, such a vaccine could theoretically eliminate the need for individual yearly shots for flu, Covid, and common cold viruses, all of which are RNA viruses, meaning their genetic composition is RNA rather than DNA.

The potential applicability to DNA viruses – like those causing chickenpox or hepatitis – remains much more uncertain and would necessitate further research.

How long does the immunity last?

In mouse studies, protection lasted for as long as three months. This duration is significantly shorter than that of traditional vaccines in humans, some of which can provide protection for many years or even a lifetime.

At present, it is unclear how long this type of vaccine might offer protection in humans.

A similarly brief immunity period in humans might be regarded as a notable drawback, but it is not necessarily a critical issue.

If the vaccine is administered every autumn, it could deliver substantial protection to at-risk individuals during the winter months, when respiratory infections are most frequent.

Even short-lived immunity, applied strategically, could be lifesaving.

What actions should be taken next?

The top priority is to show that the vaccine is safe. Since this vaccine aims to keep certain immune system parts active for a prolonged duration, it is essential to verify that it does not lead to unforeseen damage to healthy tissues.

Researchers must also determine whether the intense inflammatory reaction it causes does not heighten the risk of other infections, such as intestinal parasites, which share similar biological mechanisms with allergic reactions.

Understanding how the vaccine functions in older adults, who are more susceptible to severe respiratory diseases, is another crucial question.

As individuals age, a low-level ongoing inflammation, referred to as inflammaging, may also play a role in age-related illnesses and diminish defenses against previously encountered infections.

When can we expect the vaccine to be ready?

The lead researcher of the study, Bali Pulendran, indicates that under the most optimistic circumstances, a universal vaccine for respiratory illnesses might be introduced within five to seven years.

Nonetheless, the pace of advancement will significantly rely on the outcomes of early human trials.

If the vaccine is found to be less effective in humans compared to mice, or if safety issues arise, modifications will be necessary, prolonging the timeline at each phase.

Conversely, strong initial results could create positive momentum. In any case, creating a formulation suitable for humans, finalizing safety tests, and evaluating its effectiveness against various real-life pathogens is a comprehensive process that cannot be expedited easily.